Viking Therapeutics (VKTX) Announces Initiation of Phase 1b Clinical Trial of VK0214 in Patients with X-ALD
Go back to Viking Therapeutics (VKTX) Announces Initiation of Phase 1b Clinical Trial of VK0214 in Patients with X-ALD| ING Van Kampen Equity Growth Fund S 2 Class (NASDAQ: VKTX) | Delayed: 68.86 +3.79 (5.82%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $65.07 | 52 Week High | $5.17 | |||
| Open | $63.00 | 52 Week Low | $0.94 | |||
| Day High | $69.17 | P/E | N/A | |||
| Day Low | $62.56 | EPS | $0.00 | |||
| Volume | 3,521,971 | |||||
